Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CTKB · Nasdaq · United States · Laboratory Analytical Instruments
In shortCytek Biosciences, Inc. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -20.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -33.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -18.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 5.04× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -85.20× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 6.15 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -4.4% | 3/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 15.8% | 52/100 |
| Operating margin volatility | 10.8% | 11/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 7.1% | 56/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 128 | 164 | 193 | 200 | 201 |
| Cost of revenue | 49 | 63 | 84 | 89 | 97 |
| Gross profit | 79 | 101 | 109 | 111 | 104 |
| Research & development | 24 | 35 | 44 | 39 | 36 |
| Operating income | 9.2 | (1.8) | (28) | (21) | (40) |
| Interest expense | 1.7 | 2.6 | 2.1 | (5.2) | 0.5 |
| Pre-tax income | 5.9 | 1.3 | (16) | (5.7) | (30) |
| Income tax | 2.9 | (1.2) | (3.6) | 0.3 | 37 |
| Net income | 3 | 2.5 | (12) | (6) | (67) |
| Diluted EPS | $0.00 | $0.02 | −$0.09 | – | – |
| Diluted shares (millions) | 82 | 139 | 135 | 131 | 128 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
6.15 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026